Dominick Colangelo Sells 26,592 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares in the company, valued at $11,902,662.66. The trade was a 9.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Vericel Stock Down 0.0 %

VCEL stock opened at $45.38 on Monday. The firm has a market capitalization of $2.27 billion, a PE ratio of 756.46 and a beta of 1.78. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The stock has a 50-day simple moving average of $55.59 and a two-hundred day simple moving average of $51.84.

Analyst Ratings Changes

VCEL has been the topic of a number of recent analyst reports. Truist Financial reiterated a “buy” rating and set a $61.00 target price (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Canaccord Genuity Group lifted their price objective on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Stephens reissued an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. grew its holdings in Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 183 shares in the last quarter. Atria Investments Inc grew its holdings in Vericel by 2.4% during the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 184 shares in the last quarter. Captrust Financial Advisors grew its holdings in Vericel by 3.4% during the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 199 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock valued at $1,312,000 after buying an additional 200 shares in the last quarter. Finally, Avantax Advisory Services Inc. grew its holdings in Vericel by 1.7% during the 4th quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock valued at $758,000 after buying an additional 234 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.